MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company developing protein and antibody therapeutics, presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb®5574, a monoclonal antibody engineered using Xencor’s XmAb Fc technologies that targets the antigen CD19. In the studies, treatment with XmAb5574 achieved near complete elimination of B cells in cynomolgus monkeys, complementing previous data showing strong antitumor potency and anti-proliferative apoptotic activity similar to that of rituximab.
